According to the INTERHEART2 and the INTERSTROKE3 studies, dyslipidemias, assessed as increased levelsof apolipoprotein (ApoB/ApoA1 ratio), represented the 49.2% and the 25.9% of theattributable risk for acute myocardial infarction and stroke, respectively.Randomized controlled clinical trials have consistently demonstrated that areduction in low-density lipoprotein cholesterol (LDL-C) with statin therapy reducesthe incidence of heart attack and ischemic stroke. Here, APOB is linked to myocardial infarction.